


PENDING CLAIMS

1. (Original) A complex comprising:


a) compound of formula (I):



wherein:

each R_1 is independently hydrogen or (C_1-C_4) alkyl, optionally substituted with carboxy;

each X is independently $(CH_2)_n$ or



wherein the compound of formula I is substituted on one or more carbons other than a carbon of R_1 with one or more groups $-Y(PO_3H_2)_m$; wherein Y is a linker group; and m is 1, 2, 3, 4, 5, or 6; or a pharmaceutically acceptable salt thereof; and

b) a detectable or therapeutic radionuclide.

2. (Original) The complex of claim 1 wherein each R_1 is independently (C_1-C_4) alkyl, substituted with carboxy.

3. (Original) The complex of claim 1 wherein each R_1 is carboxymethyl or 2-carboxyethyl.


-
4. (Original) The complex of claim 1 wherein each R_1 is carboxymethyl.
 5. (Original) The complex of claim 1 wherein each n is independently 2 or 3.
 6. (Original) The complex of claim 1 wherein each n is 2.
 7. (Original) The complex of claim 1 wherein the linker group Y is about 5 angstroms to about 100 angstroms in length.
 8. (Original) The complex of claim 1 wherein the linker group Y is about 10 angstroms to about 50 angstroms in length.
 9. (Original) The complex of claim 1 wherein the compound of formula I is substituted on a carbon other than a carbon of R_1 with one or two groups $-Y(PO_3H_2)_m$, wherein m is 1, 2, 3, 4, 5, or 6.
 10. (Original) The complex of claim 1 wherein the linker group Y is an amino acid, a peptide, a saccharide, or a divalent (C_1 - C_{10})alkyl chain, optionally comprising one or more non-peroxide oxy ($-O-$), $-N(R_d)-$, or divalent aryl within the chain or at the terminus of the chain, which chain is optionally substituted on carbon with one or more oxo ($=O$), thioxo ($=S$), or hydroxy, wherein R_d is hydrogen or (C_1 - C_4)alkyl.
 11. (Original) The complex of claim 10 wherein the linker group Y is an amino acid.
 12. (Original) The complex of claim 11 wherein the amino acid is non-lipophilic.
 13. (Original) The complex of claim 10 wherein the linker group Y is a saccharide.

-
14. (Original) The complex of claim 13 wherein the saccharide is a monosaccharide, disaccharide, or trisaccharide.
15. (Original) The complex of claim 13 wherein the saccharide is a polysaccharide.
16. (Original) The complex of claim 10 wherein the linker group Y is a peptide.
17. (Original) The complex of claim 16 wherein the peptide comprises 2 to 25 amino acid residues.
18. (Original) The complex of claim 17 wherein the amino acid residues are non-lipophilic.
19. (Original) The complex of claim 10 wherein the linker group Y is a divalent (C₁-C₁₀)alkyl chain, optionally comprising one or more non-peroxide oxy (-O-), -N(R_d)-, or divalent aryl within the chain or at the terminus of the chain, which chain is optionally substituted on carbon with one or more oxo (=O), thioxo (=S), or hydroxy, wherein R_d is hydrogen or (C₁-C₄)alkyl.
20. (Original) The complex of claim 10 wherein the linker group Y is a divalent (C₁-C₁₀)alkyl chain, comprising one or more non-peroxide oxy (-O-), -N(R_d)-, or divalent aryl within the chain or at the terminus of the chain, which chain is optionally substituted on carbon with one or more oxo (=O), thioxo (=S), or hydroxy, wherein R_d is hydrogen or (C₁-C₄)alkyl.
21. (Original) The complex of claim 10 wherein the linker group Y is a divalent (C₁-C₁₀)alkyl chain, optionally comprising one or more non-peroxide oxy (-O-), -N(R_d)-, or divalent aryl within the chain or at the terminus of the chain, which chain is substituted on carbon with one or more oxo (=O), thioxo (=S), or hydroxy, wherein R_d is hydrogen or (C₁-C₄)alkyl.
22. (Original) The complex of claim 10 wherein the linker group Y is a divalent (C₁-C₁₀)alkyl chain comprising one or more non-peroxide oxy (-O-), -N(R_d)-, or divalent aryl within

the chain or at the terminus of the chain, which chain is substituted on carbon with one or more oxo (=O), thioxo (=S), or hydroxy, wherein R_d is hydrogen or (C_1-C_4) alkyl.

23. (Original) The complex of claim 1 wherein each $-Y(PO_3H_2)_m$ is independently 4-[2-(Bis-phosphonomethyl-amino)-acetyl-amino]-benzyl; 4-[4-(Bis-phosphonomethyl-carbamoyl)-butyrylamino]-benzyl; 4-(3,3-Bis-phosphono-propionyl-amino)-benzyl; 4-[4-(3-hydroxy-3,3-bis-phosphono-propylcarbamoyl)-butyrylamino]-benzyl; 4-(3-[2-(Bis-phosphonomethyl-amino)-acetyl-amino]-2-[[2-(bis-phosphonomethyl-amino)-acetyl-amino]-methyl]-propionyl-amino)-benzyl; 4-(4-{Bis-[(bis-phosphonomethyl-carbamoyl)-methyl]-carbamoyl}-butyrylamino)-benzyl; 4-{3-(3,3-Bis-phosphono-propionyl-amino)-2-[(3,3-bis-phosphono-propionyl-amino)-methyl]-[propionyl-amino]-benzyl; 4-(4-{Bis-[(3-hydroxy-3,3-bis-phosphono-propylcarbamoyl)-methyl]-carbamoyl}-butyrylamino)-benzyl; 4-{4-[(Bis-phosphono-methyl)-carbamoyl]-butyrylamino}-benzyl; or 4-[4-(Bis-[(bis-phosphono-methyl)-carbamoyl]-methyl)-carbamoyl]-butyrylamino]-benzyl.

24. (Original) The complex of claim 1 wherein the compound of formula I is a compound of formula (II):



(II)

wherein:


each R_1 is independently hydrogen or (C_1-C_4) alkyl, optionally substituted with carboxy (COOH); and each n is independently 2, 3, or 4; wherein the compound of formula (II) is substituted on one or more carbons other than a carbon of R_1 with one or more groups -

$Y(PO_3H_2)_m$; wherein Y is a linker group; and m is 1, 2, 3, 4, 5, or 6; or a pharmaceutically acceptable salt thereof.

25. (Original) The complex of claim 24 wherein each R_1 is independently (C_1-C_4) alkyl, substituted with carboxy.
26. (Original) The complex of claim 24 wherein each R_1 is carboxymethyl.
27. (Original) The complex of claim 24 wherein the compound of formula II is substituted on a carbon other than a carbon of R_1 with one or two groups $-Y(PO_3H_2)_m$.
28. (Original) The complex of claim 24 wherein the compound of formula II is substituted on carbon with one group $-Y(PO_3H_2)_m$.
29. (Original) The complex of claim 24 wherein the linker group Y is an amino acid, a peptide, a saccharide, or a divalent (C_1-C_{10}) alkyl chain, optionally comprising one or more non-peroxide oxy $(-O-)$, $-N(R_d)-$, or divalent aryl within the chain or at the terminus of the chain, which chain is optionally substituted on carbon with one or more oxo $(=O)$, thioxo $(=S)$, or hydroxy, wherein R_d is hydrogen or (C_1-C_4) alkyl.
30. (Original) The complex of claim 24 wherein the linker group Y is a divalent (C_1-C_{10}) alkyl chain, optionally comprising one or more non-peroxide oxy $(-O-)$, $-N(R_d)-$, or divalent aryl within the chain or at the terminus of the chain, which chain is optionally substituted on carbon with one or more oxo $(=O)$, thioxo $(=S)$, or hydroxy, wherein R_d is hydrogen or (C_1-C_4) alkyl.
31. (Original) The complex of claim 24 wherein each $-Y(PO_3H_2)_m$ is independently 4-[2-(Bis-phosphonomethyl-amino)-acetylamino]-benzyl; 4-[4-(Bis-phosphonomethyl-carbamoyl)-butyrylamino]-benzyl; 4-(3,3-Bis-phosphono-propionylamino)-benzyl; 4-[4-(3-hydroxy-3,3-bis-phosphono-propylcarbamoyl)-butyrylamino]-benzyl; 4-(3-[2-(Bis-phosphonomethyl-amino)-

acetylamino]-2-{{2-(bis-phosphonomethyl-amino)-acetyl-amino]-methyl}-propionylamino)-benzyl; 4-(4-{Bis-[(bis-phosphonomethyl-carbamoyl)-methyl]-carbamoyl}-butyrylamino)-benzyl; 4-{3-(3,3-Bis-phosphono-propionylamino)-2-[(3,3-bis-phosphono-propionylamino)-methyl]-[propionylamino]-benzyl; 4-(4-{Bis-[(3-hydroxy-3,3-bis-phosphono-propylcarbamoyl)-methyl]-carbamoyl}-butyrylamino)-benzyl; 4-{4-[(Bis-phosphono-methyl)-carbamoyl]-butyrylamino)-benzyl; or 4-[4-(Bis-[(bis-phosphono-methyl)-carbamoyl]-methyl)-carbamoyl]-butyrylamino]-benzyl.

32. (Original) The complex of claim 1 wherein the compound of formula I is a compound of formula III:



(III)

wherein:

each R_1 is independently hydrogen or (C_1-C_4) alkyl, optionally substituted with carboxy (COOH); and wherein the compound of formula III is substituted on one or more carbons other than a carbon of R_1 with one or more groups $-Y(PO_3H_2)_m$; wherein Y is a linker group; and m is 1, 2, 3, 4, 5, or 6; or a pharmaceutically acceptable salt thereof.

33. (Original) The complex of claim 32 wherein each R_1 is independently (C_1-C_4) alkyl, substituted with carboxy.


34. (Original) The complex of claim 32 wherein each R_1 is carboxymethyl.

35. (Original) The complex of claim 32 wherein the compound of formula III is substituted with one or two groups $-Y(PO_3H_2)_m$.

36. (Original) The complex of claim 32 wherein the compound of formula III is substituted with one group $-Y(PO_3H_2)_m$.

37. (Original) The complex of claim 32 wherein the linker group Y is an amino acid, a peptide, a saccharide, or a divalent (C₁-C₁₀)alkyl chain, optionally comprising one or more non-peroxide oxy (-O-), -N(R_d)-, or divalent aryl within the chain or at the terminus of the chain, which chain is optionally substituted on carbon with one or more oxo (=O), thioxo (=S), or hydroxy, wherein R_d is hydrogen or (C₁-C₄)alkyl.
38. (Original) The complex of claim 32 wherein the linker group Y is a divalent (C₁-C₁₀)alkyl chain, optionally comprising one or more non-peroxide oxy (-O-), -N(R_d)-, or divalent aryl within the chain or at the terminus of the chain, which chain is optionally substituted on carbon with one or more oxo (=O), thioxo (=S), or hydroxy, wherein R_d is hydrogen or (C₁-C₄)alkyl.
39. (Original) The complex of claim 32 wherein each -Y(PO₃H₂)_m is independently 4-[2-(Bis-phosphonomethyl-amino)-acetylamino]-benzyl; 4-[4-(Bis-phosphonomethyl-carbamoyl)-butyrylamino]-benzyl; 4-(3,3-Bis-phosphono-propionylamino)-benzyl; 4-[4-(3-hydroxy-3,3-bis-phosphono-propylcarbamoyl)-butyrylamino]-benzyl; 4-(3-[2-(Bis-phosphonomethyl-amino)-acetylamino]-2-[[2-(bis-phosphonomethyl-amino)-acetylamino]-methyl]-propionylamino)-benzyl; 4-(4-{Bis-[(bis-phosphonomethyl-carbamoyl)-methyl]-carbamoyl}-butyrylamino)-benzyl; 4-{3-(3,3-Bis-phosphono-propionylamino)-2-[(3,3-bis-phosphono-propionylamino)-methyl]-[propionylamino]-benzyl; 4-(4-{Bis-[(3-hydroxy-3,3-bis-phosphono-propylcarbamoyl)-methyl]-carbamoyl}-butyrylamino)-benzyl; 4-{4-[(Bis-phosphono-methyl)-carbamoyl]-butyrylamino}-benzyl; or 4-[4-(Bis-[[bis-phosphono-methyl]-carbamoyl]-methyl)-carbamoyl]-butyrylamino]-benzyl.
40. (Original) The complex of claim 32 wherein each R₁ is independently (C₁-C₄)alkyl, substituted with carboxy (COOH); and wherein the ring is substituted on carbon with a group -Y(PO₃H₂)_m; or a pharmaceutically acceptable salt thereof.

41. (Original) The complex of claim 1 wherein the compound of formula I is a compound of formula IV:



(IV)

wherein:

each R₁ is independently hydrogen or (C₁-C₄)alkyl, optionally substituted with carboxy (COOH); and each n is independently 2, 3, or 4; wherein the compound of formula IV is substituted on one or more carbons other than a carbon of R₁ with one or more groups - Y(PO₃H₂)_m; wherein Y is a linker group; and m is 1, 2, 3, 4, 5, or 6; or a pharmaceutically acceptable salt thereof.

42. (Original) The complex of claim 41 wherein each R₁ is independently (C₁-C₄)alkyl, substituted with carboxy.

43. (Original) The complex of claim 41 wherein each R₁ is carboxymethyl.

44. (Original) The complex of claim 41 wherein the compound of formula IV is substituted with one or two groups -Y(PO₃H₂)_m.

45. (Original) The complex of claim 41 wherein the compound of formula IV is substituted with one group -Y(PO₃H₂)_m.

46. (Original) The complex of claim 41 wherein the linker group Y is an amino acid, a peptide, a saccharide, or a divalent (C₁-C₁₀)alkyl chain, optionally comprising one or more non-

peroxide oxy (-O-), -N(R_d)-, or divalent aryl within the chain or at the terminus of the chain, which chain is optionally substituted on carbon with one or more oxo (=O), thioxo (=S), or hydroxy, wherein R_d is hydrogen or (C₁-C₄)alkyl.

47. (Original) The complex of claim 41 wherein the linker group Y is a divalent (C₁-C₁₀)alkyl chain, optionally comprising one or more non-peroxide oxy (-O-), -N(R_d)-, or divalent aryl within the chain or at the terminus of the chain, which chain is optionally substituted on carbon with one or more oxo (=O), thioxo (=S), or hydroxy, wherein R_d is hydrogen or (C₁-C₄)alkyl.

48. (Original) The complex of claim 41 wherein each -Y(PO₃H₂)_m is independently 4-[2-(Bis-phosphonomethyl-amino)-acetyl-amino]-benzyl; 4-[4-(Bis-phosphonomethyl-carbamoyl)-butyrylamino]-benzyl; 4-(3,3-Bis-phosphono-propionyl-amino)-benzyl; 4-[4-(3-hydroxy-3,3-bis-phosphono-propylcarbamoyl)-butyrylamino]-benzyl; 4-(3-[2-(Bis-phosphonomethyl-amino)-acetyl-amino]-2-[[2-(bis-phosphonomethyl-amino)-acetyl-amino]-methyl]-propionyl-amino)-benzyl; 4-(4-{Bis-[(bis-phosphonomethyl-carbamoyl)-methyl]-carbamoyl}-butyrylamino)-benzyl; 4-{3-(3,3-Bis-phosphono-propionyl-amino)-2-[(3,3-bis-phosphono-propionyl-amino)-methyl]-[propionyl-amino]-benzyl; 4-(4-{Bis-[(3-hydroxy-3,3-bis-phosphono-propylcarbamoyl)-methyl]-carbamoyl}-butyrylamino)-benzyl; 4-{4-[(Bis-phosphono-methyl)-carbamoyl]-butyrylamino}-benzyl; or 4-[4-(Bis-[(bis-phosphono-methyl)-carbamoyl]-methyl)-carbamoyl]-butyrylamino]-benzyl.

49. (Original) The complex of claim 1 wherein the compound of formula I is (6-{4-[2-(Bis-phosphonomethyl-amino)-acetyl-amino]-benzyl}-4,7,10-tris-carboxymethyl-1,4,7,10-tetraaza-cyclododec-1-yl)-acetic acid;
(6-{4-[4-(Bis-phosphonomethyl-carbamoyl)-butyrylamino]-benzyl}-4,7,10-tris-carboxymethyl-1,4,7,10-tetraaza-cyclododec-1-yl)-acetic acid;
{3-[4-(3,3-Bis-phosphono-propionyl-amino)-benzyl]-4,7,10-tris-carboxymethyl-1,4,7,10-tetraaza-cyclododec-1-yl}-acetic acid;

(4,7,10-Tris-carboxymethyl-3-{4-[4-(3-hydroxy-3,3-bis-phosphonopropyl-carbamoyl)-butyrylamino]-benzyl}-1,4,7,10-tetraaza-cyclododec-1-yl)-acetic acid;
{3-[4-(3-[2-(Bis-phosphonomethyl-amino)-acetyl-amino]-2-{[2-(bis-phosphonomethyl-amino)-acetyl-amino]-methyl}-propionyl-amino)-benzyl]-4,7,10-tris-carboxymethyl-1,4,7,10-tetraaza-cyclododec-1-yl}-acetic acid;
{6-[4-(4-{Bis-[(bis-phosphonomethyl-carbamoyl)-methyl]-carbamoyl}-butyrylamino)-benzyl]-4,7,10-tris-carboxymethyl-1,4,7,10-tetraaza-cyclododec-1-yl}-acetic acid;
[3-(4-{3-(3,3-Bis-phosphono-propionyl-amino)-2-[(3,3-bis-phosphono-propionyl-amino)-methyl]-propionyl-amino}-benzyl)-4,7,10-tris-carboxymethyl-1,4,7,10-tetraaza-cyclododec-1-yl]-acetic acid;
{6-[4-(4-{Bis-[(3-hydroxy-3,3-bis-phosphono-propyl-carbamoyl)-methyl]-carbamoyl}-butyrylamino)-benzyl]-4,7,10-tris-carboxymethyl-1,4,7,10-tetraaza-cyclododec-1-yl}-acetic acid;
[6-(4-{4-[(Bis-phosphono-methyl)-carbamoyl]-butyrylamino}-benzyl)-4,7,10-tris-carboxymethyl-1,4,7,10-tetraaza-cyclododec-1-yl]-acetic acid; or
(6-{4-[4[(Bis-[(bis-phosphono-methyl)-carbamoyl]-methyl]-carbamoyl)-butyrylamino]-benzyl}-4,7,10-tris-carboxymethyl-1,4,7,10-tetraaza-cyclododec-1-yl)-acetic acid.

50. (Original) The complex of claim 1 which comprises a detectable radionuclide.
51. (Original) The complex of claim 50 wherein the detectable radionuclide is Technetium-99m, Ruthenium-97, Indium-111, Gallium-67 or -68, or Lead-203.
52. (Original) The complex of claim 1 which comprises a therapeutic radionuclide.
53. (Original) The complex of claim 52 wherein the therapeutic radionuclide is Holmium-166, Yttrium-90, Samarium-153, or Gadolinium-159.
54. (Original) The complex of claim 52 wherein the therapeutic radionuclide is Holmium-166.

55. (Original) A method for detecting the presence or absence of a calcified tissue target site within a mammal, comprising:
administering to the mammal a detectable dose of a complex of claim 50; and
detecting the compound in the mammal to determine the presence or absence of the target site.
56. (Original) A therapeutic method for suppressing bone marrow in a mammal in need of such therapy comprising administering to the mammal, an effective bone marrow suppressing amount of a complex of claim 52.
57. (Original) A therapeutic method for treating cancer in a mammal in need of such therapy comprising administering to the mammal, an effective amount of a complex of claim 52.
58. (Original) A therapeutic method for treating bone pain in a mammal in need of such therapy comprising administering to the mammal, an effective amount of a complex of claim 52.
59. (Cancelled)
60. (Previously Presented) A therapeutic method for treating a condition treatable with stem cell transplantation, with or without gene therapy, that utilizes bone marrow ablation, in a mammal in need of such therapy comprising administering to the mammal an effective amount of a complex of claim 52.
61. (Previously Presented) A therapeutic method for treating Crohn's disease, rheumatoid arthritis, multiple sclerosis, osteoporosis, osteopenia, osteomyelitis, Paget's disease, sickle cell anemia, or a lysosomal or peroxisomal storage disease, in a mammal in need of such therapy comprising administering to the mammal an effective amount of a complex of claim 52.
62. (Original) A pharmaceutical composition comprising the complex of claim 1 and a pharmaceutically acceptable carrier.

63. (Previously Presented) A therapeutic method for treating an infection in a mammal in need of such therapy comprising administering to the mammal, an effective amount of a complex of claim 52.